Prestige BioPharma Limited
Korea ExchangeTotal Valuation
Prestige BioPharma Limited carries a market capitalization of 362.98B, placing it among publicly traded companies globally. Its enterprise value stands at 689.57B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 362.98B |
| Enterprise Value | 689.57B |
Share Statistics
Prestige BioPharma Limited currently has 12.02M shares outstanding.
| Shares Outstanding | 12.02M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Prestige BioPharma Limited trades at a trailing price-to-earnings ratio of 106.48. The price-to-sales ratio is 36.65, and the price-to-book ratio stands at 1.32.
| PE Ratio | 106.48 |
| PS Ratio | 36.65 |
| PB Ratio | 1.32 |
| P/TBV Ratio | 1.73 |
| P/FCF Ratio | -36.33 |
| P/OCF Ratio | -14.27 |
Enterprise Valuation
| EV / Sales | 42.97 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Prestige BioPharma Limited maintains a current ratio of 0.85, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.85 |
| Quick Ratio | 0.53 |
| Debt / Equity | 15.49 |
| Debt / EBITDA | -1.03 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -12.08 |
| Return on Assets (ROA) | -7.27 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.84 |
Taxes
| Income Tax | -335.54M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Prestige BioPharma Limited's stock has declined approximately -68.09297% over the past 52 weeks. The 50-day moving average sits at 7,382.80, while the 200-day moving average is 10,754.25.
| Beta (5Y) | N/A |
| 52-Week Price Change | -68.09297% |
| 50-Day Moving Average | 7,382.80 |
| 200-Day Moving Average | 10,754.25 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Prestige BioPharma Limited generated 16.05B in revenue and converted that into -56.74B in net income, yielding earnings per share of -1,311.04. EBITDA reached -83.60B, while operating income came in at -83.60B.
| Revenue | 16.05B |
| Gross Profit | -35.36B |
| Operating Income | -83.60B |
| Pretax Income | -79.10B |
| Net Income | -56.74B |
| EBITDA | -83.60B |
| EBIT | -83.60B |
| Earnings Per Share (EPS) | -1,311.04 |
Balance Sheet
Prestige BioPharma Limited holds 65.89B in cash and equivalents against 85.94B in total debt, resulting in a net debt position of 21.51B. Total book value stands at 447.25B, with working capital of -18.67B providing operational flexibility.
| Cash & Cash Equivalents | 65.89B |
| Total Debt | 85.94B |
| Net Debt | 21.51B |
| Equity (Book Value) | 447.25B |
| Book Value Per Share | 7,444.34 |
| Working Capital | -18.67B |
Cash Flow
Prestige BioPharma Limited produced -41.21B in operating cash flow over the past twelve months. After subtracting -25.02B in capital expenditures, free cash flow totaled -66.24B - equivalent to -1,102.46 per share.
| Operating Cash Flow | -41.21B |
| Capital Expenditures | -25.02B |
| Free Cash Flow | -66.24B |
| FCF Per Share | -1,102.46 |
Margins
Prestige BioPharma Limited operates with a gross margin of -52.33, reflecting its pricing power and cost economics. The operating margin of -520.99 and net profit margin of -353.56 provide insight into operational efficiency.
| Gross Margin | -52.33 |
| Operating Margin | -520.99 |
| Pretax Margin | -492.93 |
| Profit Margin | -353.56 |
| EBITDA Margin | -520.99 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 11.37 |
| FCF Yield | -2.75 |
Scores
Prestige BioPharma Limited posts an Altman Z-Score of 0.27, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 0.27 |